XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
GOODWILL AND INTANGIBLE ASSETS
 12 Months Ended
Dec. 25, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table provides a rollforward of the Company’s goodwill:
Adjustments to GoodwillAdjustments to Goodwill
December 28, 2019AcquisitionsForeign ExchangeDecember 26, 2020AcquisitionsDivestituresForeign ExchangeDecember 25, 2021
(in thousands)
RMS$56,586 $229,654 $1,519 $287,759 $— $(4,129)$(106)$283,524 
DSA2,350,223 (629)33,536 2,383,130 123,091 — (28,715)2,477,506 
Manufacturing138,756 — 4,523 143,279 851,828 (27,764)(11,492)955,851 
Gross carrying amount2,545,565 229,025 39,578 2,814,168 974,919 (31,893)(40,313)3,716,881 
Accumulated impairment loss - DSA(1,005,000)— — (1,005,000)— — — (1,005,000)
Goodwill$1,540,565 $1,809,168 $2,711,881 
Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2021, 2020 and 2019, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired.
The increase in goodwill during fiscal year 2021 related primarily to the acquisitions of Cognate and Vigene in the Manufacturing reportable segment and Distributed Bio and Retrogenix in the DSA reportable segment. The decreases in the RMS and Manufacturing reportable segments was a result of the sales of RMS Japan and CDMO Sweden, respectively. The increase in goodwill during fiscal year 2020 related primarily to the acquisitions of HemaCare and Cellero in the RMS reportable segment.
Intangible Assets, Net
The following table displays intangible assets, net by major class:
 December 25, 2021December 26, 2020
GrossAccumulated
Amortization 		NetGrossAccumulated
Amortization		Net
(in thousands)
Backlog$12,577 $(9,517)$3,060 $29,233 $(29,233)$— 
Technology135,764 (95,454)40,310 130,907 (81,305)49,602 
Trademarks and trade names13,086 (3,448)9,638 15,870 (5,648)10,222 
Other35,231 (8,445)26,786 20,903 (14,633)6,270 
Other intangible assets196,658 (116,864)79,794 196,913 (130,819)66,094 
Client relationships1,475,757 (494,359)981,398 1,137,331 (415,826)721,505 
Intangible assets$1,672,415 $(611,223)$1,061,192 $1,334,244 $(546,645)$787,599 
The increase in intangible assets, net during fiscal year 2021 related primarily to the acquisitions of Cognate, Distributed Bio, Retrogenix, and Vigene.
Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2021, 2020 and 2019 was $124.9 million, $111.9 million and $89.5 million, respectively. As of December 25, 2021, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:
Fiscal YearAmortization Expense
(in thousands)
2022$143,202 
2023131,385 
2024118,295 
2025110,830 
2026103,485